Chronic heart failure patients are subject to high rates of mortality and morbidity and frequent readmissions to the hospital mean that chronic heart failure also represents a significant…
Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs),…
Renal anemia is a serious and common complication of chronic kidney disease (CKD). An in-depth examination of the drivers and obstacles facing nephrologists provides greater insights on product…
Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses…
Chronic pain is a broad term encompassing many nociceptive, inflammatory, and neuropathic pain subtypes that can result from complex mechanisms affecting multiple pathophysiological pathways in the…
Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…
Abstract: The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
The United States has seen a dramatic rise in the prevalence of chronic kidney disease (CKD) and its sequelae—namely, diabetes and hypertension. Patients with CKD are typically co-managed by many…
The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years,…
Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label…
Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but the impact on CV risk varies by lipid disorder. Treatment has centered mainly on reducing the levels of atherogenic…
Each year in the United States, more than 17,000 patients suffering from renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these…
Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and…